Audit a URL →

Sign in Sign up free

Loading…

Weekly · Sunday Morning

Five longevity claims.
Worth your time.
Every Sunday.

Last Sunday

Rapamycin extends mouse lifespan 9–14%
NAD+ precursors reverse aging in humans
Blue-light glasses improve sleep quality
Walking 10 min after meals blunts glucose
Verdict change — caffeine half-life downgraded

5 audits·1 verdict change·0 affiliate links·Every Sunday

Joining 1,247 readers — founders, MDs, and longevity-obsessed people who fact-check their own health decisions.

Browse

Decisions Claims Content Creators

Product

Audit a URL Sunday roundup API (soon)Pricing

About

FAQ Methodology Editorial Standards Corrections Press & brand RSS feed

Legal

Terms of Service Privacy Policy DMCA

Finally, something serious in this space.
Because we actually read the papers.

© 2026 Whalespan. Independent, evidence-graded longevity.

Pros & cons of GLP-1 weight loss drugs | Dr. Ralph DeFronzo — Whalespan

Content›Video›Pros & cons of GLP-1 weight …

Pros & cons of GLP-1 weight loss drugs | Dr. Ralph DeFronzo

Peter Attia12m · 2025-03-01

Claims Made

28

Claims Supported

21

Support Rate

75%

Support rate

21 of 28 claims supported

21 supported7 partial / not

Claims from this content

26

✓Well SupportedGLP-1 receptor agonists demonstrate a trend of increasing efficacy and decreasing toxicity with successive generations of drugs.◐Partially SupportedTests for myostatin inhibition in mice showed a statistically significant but small decrease in body fat, with unclear takeaways due to lack of exercise control.✓Well SupportedGLP-1 receptor agonists are generally safe but must be initiated slowly due to potential gastrointestinal toxicity.◐Partially SupportedFor sarcopenic elderly individuals, the FDA will likely require an increase in lean body mass to be accompanied by improved strength, not just lean mass alone.Partially Supported

More from Peter Attia

Peter Attia on Zone 2 Cardio

Peter Attia on Rapamycin (with Matt Kaeberlein)

Attia walks back the clinic protocol: too aggressive for healthy adults

Discussion

Native comments, Twitter mentions, and Reddit threads about this content — surfaced together so the conversation isn't fragmented across platforms.

M

Share your read of this content…

Posting publicly as you · linked to your social profiles

Sort by:

AV

A. Volkovreader

4h

Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.

NP

N. Park

2d

Would love a "what would change this verdict" RSS feed. Sign me up if it exists.

◐

The FDA has established criteria for approving drugs for sarcopenic disease.

◐Partially SupportedIn significant weight loss, losing a majority of fat mass with only a small fraction of lean mass is acceptable.

◐Partially SupportedWeight loss through bypass surgery may improve VO2 max by reducing fat that impedes lung function, cardiac contraction, and causes myocardial lipotoxicity.

◐Partially SupportedTreating a 105-year-old with diabetes with hypoglycemia-inducing drugs may be reasonable if weight and other factors are monitored, given beta-cell effects.

?Limited ResearchIt is unknown if GLP-1 receptor agonists are appropriate for a lean 80-year-old person with a family history of longevity and diabetes.

◐Partially SupportedIncreasing follistatin is a more direct way to inhibit myostatin than interfering with the Akt1/2 system.

◐Partially SupportedMyostatin inhibitors are likely effective in fully developed adult humans, not just during development.

◐Partially SupportedInhibiting myostatin increases the expression of striated muscle, including cardiac muscle, through the Akt/mTOR pathway.

◐Partially SupportedGrip strength, leg extension, and bench press are preferred measures of strength over the six-minute walk test.

◐Partially SupportedResistance training increases insulin sensitivity and functional strength, and pharmacological interventions should aim to replicate these effects.

◐Partially SupportedMyostatin inhibitors have passed toxicity tests in Phase 1 trials and have not shown adverse effects, allowing them to proceed to Phase 2.

◐Partially SupportedPreventing muscle loss with a myostatin inhibitor during significant weight loss could lead to a very low percentage of body fat.

◐Partially SupportedDrug-induced increases in muscle mass should improve glucose disposal and insulin sensitivity.

◐Partially SupportedLean body mass measurements may not accurately reflect true muscle mass and can be a poor indicator.

◐Partially SupportedMyostatin inhibitors are relevant for sarcopenic, elderly individuals at high risk of falls, morbidity, and mortality.

✕Not SupportedThe six-minute walk test is an inadequate measure of functional improvement.

◐Partially SupportedSignificant weight loss (20-30%) can lead to substantial muscle mass loss.

◐Partially SupportedImprovements in insulin sensitivity and corrected cardiovascular risk factors can lead to significant health benefits despite potential muscle mass loss during dieting.

◐Partially SupportedMyostatin inhibitor drugs have passed Phase 1 toxicity trials without significant adverse effects.

◐Partially SupportedFollowing significant weight loss, relative strength, mobility, and VO2 max can improve.

◐Partially SupportedAntibodies or receptor interference are direct methods to inhibit myostatin.

◐Partially SupportedThe FDA may not give credit for drugs that improve insulin sensitivity and glucose disposal if there are perceived easier ways to achieve these improvements.